W. Powley

发表

Objective measurement of cough in otherwise healthy volunteers with acute cough

J. Smith, A. Kelsall, K. Sunger, 2012, European Respiratory Journal.

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

S. Rosenkranz, D. Budd, C. Opitz, 2021, Pulmonary circulation.

Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study

J. Hohlfeld, D. Budd, A. Lazaar, 2021, Pulmonary Therapy.

Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial

A. Ellis, W. Powley, D. Tsitoura, 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Study to Explore the Association of the Renin-Angiotensin System and Right Ventricular Function in Mechanically Ventilated Patients

D. Budd, A. Lazaar, D. Hall, 2022, Journal of clinical medicine.

Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

R. Emmins, A. Lazaar, A. Lewis, 2015, Clinical and experimental immunology.

Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement

K. Biggadike, C. Ambery, W. Powley, 2015, Clinical pharmacology and therapeutics.

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Akram Khan, T. Albertson, J. Ronco, 2017, Critical Care.

Title A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Akram Khan, T. Albertson, J. Ronco, 2017 .

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

A. May, D. Lipson, J. Christie, 2015, Critical care medicine.

Canadian Society of Allergy and Clinical Immunology annual scientific meeting 2016

Young Woong Kim, H. Pasterkamp, T. Schuster, 2017, Allergy, Asthma & Clinical Immunology.

Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study

Dave Singh, J. Hohlfeld, Laurie A. Lee, 2020, PloS one.

Intranasal GSK2245035 induces prolonged reductions in nasal responsiveness to allergen

Laurie A. Lee, A. Ellis, W. Powley, 2015 .

A randomised, placebo-controlled pilot study of a nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury.

G. Perkins, D. Thickett, D. McAuley, 2020, European Journal of Anaesthesiology.

A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

G. Perkins, D. Thickett, D. McAuley, 2020, European Journal of Anaesthesiology.